GHK-Cu Price in Australia: A$69.99 for 50mg

Current GHK-Cu price in Australia

Pillar Research lists GHK-Cu 50mg at A$69.99 per vial, held and dispatched from Australian stock. A 100mg presentation is available to preorder from the same product page. The product page is the live source for price and availability; this article explains what sits behind the number.

Why the milligram figure needs reading carefully

GHK-Cu is not a plain peptide. It is a tripeptide (glycyl-L-histidyl-L-lysine) in complex with copper, so a vial contains peptide plus co-ordinated copper, and the two are weighed differently depending on what the label is describing. This is the single most common source of confusion when comparing copper-peptide prices between suppliers.

The released Pillar Research batch makes the distinction explicit. Batch 2026-210952 reports a net content of 71.02mg GHK-Cu (59.09mg GHK; 11.93mg copper). In other words, the labelled 50mg refers to the peptide portion, while the total complex in the vial weighs more once the co-ordinated copper is counted.

What the listed price includes

• Declared strength: 50mg of lyophilised GHK-Cu research material per vial.
• Reported purity: 99.815% for batch 2026-210952, analysed by Janoshik.
• Identity result: Sample reported as GHK-Cu, reported separately from the purity figure.
• Stated composition: 71.02mg GHK-Cu (59.09mg GHK; 11.93mg copper), so the peptide and copper fractions are both documented.
• Batch record: a batch-specific GHK-Cu certificate of analysis tied to the material supplied.
• Local fulfilment: Australian stock and dispatch, not international transshipment.

50mg or 100mg: which listing to price against

Both presentations are the same compound from the same supply chain, and both carry their own batch report. The 50mg vial at A$69.99 is the in-stock line; the 100mg is a preorder with its own separately analysed batch. Price per milligram favours the larger vial, but that only matters if the material will be used within its documented handling window — a larger vial that sits unused is not cheaper in any meaningful sense.

Both strengths are selected on the same product page rather than living at separate addresses, so the batch report and stock status for whichever presentation is chosen are visible in one place. If a comparison elsewhere quotes a per-milligram figure, check whether it is derived from a strength that supplier actually holds, or from a larger vial that is out of stock.

How to compare GHK-Cu offers

Start with price per stated milligram, then verify that the stated milligram means the same thing on both pages. After that, the checks are the same as for any research peptide.

• Does the label distinguish the peptide mass from the copper-complex mass?
• Is the price in AUD, and is any shipping charge identified separately?
• Is the batch report dated, numbered, and matched to the vial being sold?
• Are identity and purity treated as two separate analytical questions?
• Is the stock genuinely held in Australia, or is the page collecting preorders?

The COA review checklist and the identity-versus-purity guide set out a method-aware way to document those checks.

What the research literature covers

GHK-Cu has been studied for copper co-ordination and for its behaviour in skin-model systems. Published work includes copper-binding characterisation in a zebrafish model^[1] and in-vitro penetration work on a copper tripeptide in skin preparations.^[2] These are laboratory findings about the molecule and its handling, not evidence of outcomes in people.

For the fuller research picture, including the historical characterisation literature, see the GHK-Cu research overview.

Price, stock and dispatch can change

Price-intent pages go stale when a figure is copied into several places at once. Pillar Research treats the product record as the source of truth and links this article straight back to it. Verify the live A$69.99 price, stock label and batch COA on the product page before ordering.

Compliance reminder

GHK-Cu is supplied for research and educational purposes only. It is not listed on the Australian Register of Therapeutic Goods (ARTG) and must not be consumed by humans or animals. All experimental use should follow institutional safety guidelines and relevant regulations.

Comparing copper-peptide options? View GHK-Cu in Australia. For related research, see the GHK-Cu research overview and the KLOW blend identity review, which covers GHK-Cu as a blend component.